Note: Biopta (Glasgow, UK and Maryland, USA) is now REPROCELL’s Center for predictive Drug Discovery.
Note: Reinnervate (Durham, UK) is now part of REPROCELL’s Center for predictive Drug Discovery.
On the REPROCELL blog
Latest
Subcutaneous Artery Assays Help Us to Understand Blood Pressure Regulation
Explore how subcutaneous artery assays enhance understanding of blood pressure regulation and aid in the development of safer, more effective cardiovascular drugs.
07 July 2025
Able Biott Single-use Bioreactors Enhance the Development of Disease Models and Cell Therapy
Discover how Able Biott single-use bioreactors enhance disease modeling and cell therapy development through scalable, efficient iPSC culture solutions.
03 July 2025
Why mRNA Reprogramming Is the Key to Safer and Faster iPSC Generation?
Discover how mRNA reprogramming enhances the safety, efficiency, and scalability of iPSC generation for therapeutic applications. Explore REPROCELL's innovative technologies and services.
10 June 2025
New Therapeutic Targets: The Role of IL17-Related Genes in Precision Medicine
Discover how IL-17 related genes could revolutionize psoriasis treatment, offering new therapeutic targets and paving the way for precision medicine advancements.
09 June 2025
Balancing Efficacy and Cognitive Health In Bladder Assays
New approaches in OAB treatment focus on balancing efficacy and cognitive health, using alternatives to anticholinergics and personalized medicine to improve patient outcomes.
23 May 2025
.jpg?width=800&height=450&name=Biopta%20(Scottish%20Life%20Sciences).jpg)
